Skip to main content
In stock|Targeted Therapy

Olutasidenib

Oncology TypeSolid Tumour
Drug Class / MechanismRET / MET / KRAS / IDH Inhibitor
No Image
Description

Olutasidenib is classified as a RET / MET / KRAS / IDH Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryTargeted Therapy
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3